Vicebio
London
About Vicebio
Vicebio develops next-generation vaccines, focusing on respiratory disease prevention using its Molecular Clamp technology. The company aims to deliver broad protection and ready-to-use formulations. It has a pipeline of multipathogen respiratory vaccines to address global health challenges.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $100.0M
- Funding stage: M&A
- Last round: Series B (Sep 2024)
- Website: vicebio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/vicebio-42771 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.